Paragonix Partners with Southwest Transplant Alliance to Provide Advanced Organ Preservation
Innovation Spotlight: Paragonix Technologies, Inc.
CAMBRIDGE, MASSACHUSETTS, May 24, 2021- Paragonix Technologies announced a partnership with Southwest Transplant Alliance(STA) to provide advanced organ preservation technology as part of both organization’s ongoing work to save lives through organ donation and transplantation. Under this new partnership, Paragonix will provide the technology, clinical support and education on the advanced preservation capabilities delivered by the Paragonix SherpaPak® Cardiac Transport System.
“STA’s organ recovery center – The Legacy Center – is a hub for innovation within our industry. We are committed to providing more healthy organs for transplant through partnerships like this one with Paragonix”
The Paragonix system is an FDA-cleared donor heart preservation system designed to ensure donor hearts are transported under optimal preservation conditions. Recently, at the International Society of Heart and Lung Transplantation, a group of researchers presented an international multi-center study of 223 patients comparing the Paragonix SherpaPak CTS to traditional ice storage. The investigators found improved outcomes such as shortened intensive care unit (ICU) length-of-stay for patients receiving hearts preserved by the Paragonix system.
“This partnership is a real change to the way donor heart preservation technology can be deployed. STA brings world class surgical services and facilities, and together we believe we can enable access to this technology for more transplant centers,” said Dr. Lisa Anderson, CEO of Paragonix Technologies.
“STA’s organ recovery center – The Legacy Center – is a hub for innovation within our industry. We are committed to providing more healthy organs for transplant through partnerships like this one with Paragonix,” said President and CEO of Southwest Transplant Alliance Patti Niles.
About Paragonix Technologies
Paragonix Technologies designs, produces, and markets organ preservation and transport devices that safeguard organs during the journey between donor and recipient patients. Our award-winning devices mitigate risk in an otherwise high stakes environment. The Paragonix systems incorporate clinically proven and medically trusted cold preservation techniques in a novel suspension system to provide unprecedented physical and thermal protection. The Paragonix SherpaPak® Cardiac Transport System and the LUNGguard™ Donor Lung Preservation System are the only commercially available FDA-cleared and CE-marked hypothermic transport devices for heart and lung preservation. Paragonix is also developing transport devices for the liver, kidney and pancreas— designed to improve donor organ quality and extend donor organ preservation time.